RAPT THERAPEUTICS INC (RAPT) Stock Price, Quote, News and Overview
NASDAQ:RAPT - Nasdaq - US75382E1091 - Common Stock - Currency: USD
RAPT Quote, Performance and Key Statistics
1.13
+0.01 (+0.89%)
The current stock price of RAPT is 1.13 USD. In the past month the price decreased by -4.24%. In the past year, price decreased by -87.56%.
RAPT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About RAPT
Company Profile
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2019-10-31. The firm is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
Company Info
RAPT THERAPEUTICS INC
561 Eccles Ave
South San Francisco CALIFORNIA 94080 US
CEO: Brian Wong
Employees: 70
Company Website: https://rapt.com/
Investor Relations: https://investors.rapt.com/
Phone: 16504899000
RAPT THERAPEUTICS INC / RAPT FAQ
What is the stock price of RAPT THERAPEUTICS INC today?
The current stock price of RAPT is 1.13 USD. The price increased by 0.89% in the last trading session.
What is the ticker symbol for RAPT THERAPEUTICS INC stock?
The exchange symbol of RAPT THERAPEUTICS INC is RAPT and it is listed on the Nasdaq exchange.
On which exchange is RAPT stock listed?
RAPT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RAPT THERAPEUTICS INC stock?
12 analysts have analysed RAPT and the average price target is 5.1 USD. This implies a price increase of 351.33% is expected in the next year compared to the current price of 1.13. Check the RAPT THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RAPT THERAPEUTICS INC worth?
RAPT THERAPEUTICS INC (RAPT) has a market capitalization of 149.17M USD. This makes RAPT a Micro Cap stock.
How many employees does RAPT THERAPEUTICS INC have?
RAPT THERAPEUTICS INC (RAPT) currently has 70 employees.
What are the support and resistance levels for RAPT THERAPEUTICS INC (RAPT) stock?
RAPT THERAPEUTICS INC (RAPT) has a support level at 1.13 and a resistance level at 1.26. Check the full technical report for a detailed analysis of RAPT support and resistance levels.
Should I buy RAPT THERAPEUTICS INC (RAPT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RAPT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RAPT, evaluating the profitability, health, valuation and growth aspects
- RAPT THERAPEUTICS INC (RAPT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RAPT THERAPEUTICS INC (RAPT) Sales and EPS estimates to see what analysts future expectations are.
- RAPT THERAPEUTICS INC (RAPT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RAPT THERAPEUTICS INC (RAPT) Insider and Institutional Ownership to learn about the owners and their transactions.
- RAPT THERAPEUTICS INC (RAPT) Stock Chart to make your own analysis
- RAPT THERAPEUTICS INC (RAPT) Latest news and press-releases to stay up to date.
Does RAPT THERAPEUTICS INC (RAPT) stock pay dividends?
RAPT does not pay a dividend.
When does RAPT THERAPEUTICS INC (RAPT) report earnings?
RAPT THERAPEUTICS INC (RAPT) will report earnings on 2025-05-07, before the market open.
What is the Price/Earnings (PE) ratio of RAPT THERAPEUTICS INC (RAPT)?
RAPT THERAPEUTICS INC (RAPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.11).
What is the Short Interest ratio of RAPT THERAPEUTICS INC (RAPT) stock?
The outstanding short interest for RAPT THERAPEUTICS INC (RAPT) is 2.15% of its float. Check the ownership tab for more information on the RAPT short interest.
RAPT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RAPT. When comparing the yearly performance of all stocks, RAPT is a bad performer in the overall market: 91.45% of all stocks are doing better.
RAPT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RAPT. No worries on liquidiy or solvency for RAPT as it has an excellent financial health rating, but there are worries on the profitability.
RAPT Financial Highlights
Over the last trailing twelve months RAPT reported a non-GAAP Earnings per Share(EPS) of -3.11. The EPS decreased by -2.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -94.69% | ||
| ROE | -110.26% | ||
| Debt/Equity | 0 |
RAPT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to RAPT. The Buy consensus is the average rating of analysts ratings from 12 analysts.